nach oben

Erschienen in:

01.02.2010 | Review

Multimer technologies for detection and adoptive transfer of antigen-specific T cells

verfasst von: Rosaely Casalegno-Garduño, Anita Schmitt, Junxia Yao, Xinchao Wang, Xun Xu, Mathias Freund, Michael Schmitt

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Identification and purification of antigen-specific T cells without altering their functional status are of high scientific and clinical interest. Staining with major histocompatibility complex (MHC)-peptide multimers constitutes a very powerful method to study antigen-specific T-cell subpopulations, allowing their direct visualization and quantification. MHC-peptide multimers, such as dimers, tetramers, pentamers, streptamers, dextramers and octamers have been used to evaluate the frequency of CD8⁺ T cells, specific for tumor/leukemia-associated antigens as well as for viral antigens, e.g., CMVpp65 and EBV-EBNA. Moreover, MHC-peptide multimers have been used for rapid and efficient ex vivo isolation and expansion of T cells. A recent development in the field of MHC-peptide multimers led to the purification of CD8⁺ T cells specific for leukemia antigens. This might help to select leukemia-specific donor lymphocyte infusions (DLIs), thus allowing dissection of the noxious graft-versus-host disease (GvHD) from beneficial anti-viral and even anti-leukemic effects. This review covers different types of MHC-peptide multimers and their applications, as well as the impact that multimers might have on further development of DLIs.

Hebart H, Rauser G, Stevanovic S et al (2003) A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal immune responses in patients after allogeneic stem cell transplantation. Exp Hematol 31:966–973CrossRefPubMed

Manley TJ, Luy L, Jones T et al (2004) Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8⁺ cytotoxic T-cell response in natural infection. Blood 104:1075–1082CrossRefPubMed

Grigoleit GU, Kapp M, Hebart H et al (2007) Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T-lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis 196:699–704CrossRefPubMed

Chattopadhyay PK, Hogerkorp CM, Roederer M (2008) A chromatic explosion: the development and future of multiparameter flow cytometry. Immunology 125:441–449CrossRefPubMed

Duplan V, Suberbielle E, Napper CE et al (2007) Tracking antigen-specific CD8⁺ T cells in the rat using MHC class I multimers. J Immunol Methods 320:30–39CrossRefPubMed

Svensson A, Nordström I, Sun JB, Eriksson K (2005) Protective immunity to genital herpes simplex [correction of simpex] virus type 2 infection is mediated by T-bet. J Immunol 174:6266–6273PubMed

Binder RJ, Srivastava PK (2005) Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8⁺ T cells. Nat Immunol 6:593–599CrossRefPubMed

Knabel M, Franz TJ, Schiemann M et al (2002) Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 8:631–637CrossRefPubMed

Batard P, Peterson DA, Devêvre E et al (2006) Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8⁺ T cells. J Immunol Methods 310:136–148CrossRefPubMed

10.

Guillaume P, Legler DF, Boucheron N et al (2003) Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce FAS-dependent apoptosis. J Biol Chem 278:4500–4509CrossRefPubMed

11.

Schneck JP (2000) Monitoring antigen-specific T cells using MHC-Ig dimers. Immunol Invest 29:163–169CrossRefPubMed

12.

Dal Porto J, Johansen TE, Catipović B et al (1993) A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci USA 90:6671–6675CrossRefPubMed

13.

Greten TF, Schneck JP (2002) Development and use of multimeric major histocompatibility complex molecules. Clin Diagn Lab Immunol 9:216–220PubMed

14.

Neudorfer J, Schmidt B, Huster KM et al (2007) Reversible HLA multimers (streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 320:119–131CrossRefPubMed

15.

Altman JD, Moss PA, Goulder PJ et al (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96CrossRefPubMed

16.

Doherty PC, Christensen JP (2000) Accessing complexity: the dynamics of virus-specific T-cell responses. Annu Rev Immunol 18:561–592CrossRefPubMed

17.

Wooldridge L, Lissina A, Cole D et al (2009) Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 126:147–164CrossRefPubMed

18.

Junttila MR, Saarinen S, Schmidt T et al (2005) Single-step Strep-tag purification for the isolation and identification of protein complexes from mammalian cells. Proteomics 5:1199–1203CrossRefPubMed

19.

Newell EW, Klein LO, Yu W, Davis MM (2009) Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods 6:497–499CrossRefPubMed

20.

Hadrup SR, Bakker AH, Shu CJ et al (2009) Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 6:520–526CrossRefPubMed

21.

Hardrup SR, Toebes M, Rodenko B et al (2009) High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol 524:383–405CrossRef

22.

Bakker AH, Hoppes R, Linnemann C et al (2008) Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci USA 105:3825–3830CrossRefPubMed

23.

Barnes E, Ward SM, Kasprowicz VO et al (2004) Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8⁺ T cells. Eur J Immunol 34:1570–1577CrossRefPubMed

24.

Harcourt GC, Scriba TJ, Semmo N et al (2006) Identification of key peptide-specific CD4⁺ T cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clin Exp Immunol 146:203–210CrossRefPubMed

25.

Scriba TJ, Purbhoo M, Day CL et al (2005) Ultrasensitive detection and phenotyping of CD4⁺ T cells with optimized HLA class II tetramer staining. J Immunol 175:6334–6343PubMed

26.

Melenhorst JJ, Scheinberg P, Chattopadhyay PK et al (2008) High avidity myeloid leukemia-associated antigen-specific CD8⁺ T cells preferentially reside in the bone marrow. Blood 113:2238–2244CrossRefPubMed

27.

Bouquié R, Bonnin A, Bernardeau K et al (2009) A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor-specific T lymphocytes. Cancer Immunol Immunother 58:553–566CrossRefPubMed

28.

Greten TF, Slansky JE, Kubota R et al (1998) Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8⁺ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci USA 95:7568–7573CrossRefPubMed

29.

Lee PP, Yee C, Savage PA et al (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med 5:677–685CrossRefPubMed

30.

Busch DH, Pamer EG (1998) MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. J Immunol 160:4441–4448PubMed

31.

Keenan RD, Ainsworth J, Khan N et al (2001) Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol 115:428–434CrossRefPubMed

32.

Appay V, Nixon DF, Donahoe SM et al (2000) HIV-specific CD8⁺ T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192:63–75CrossRefPubMed

33.

Choi EM, Chen JL, Wooldridge L et al (2003) High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J Immunol 171:5116–5123PubMed

34.

Oelke M, Maus MV, Didiano D et al (2003) Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 9:619–624CrossRefPubMed

35.

Rauser G, Einsele H, Sinzger C et al (2003) Rapid generation of combined CMV-specific CD4⁺ and CD8⁺ T-cell lines for adoptive transfer into allogeneic stem cell transplant recipients. Blood 103:3565–3572CrossRefPubMed

36.

Widmann T, Sester U, Gartner BC et al (2008) Levels of CMV-specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One 3:1–9CrossRef

37.

Savage PA, Boniface JJ, Davis MM (1999) A kinetic basis for T-cell receptor repertoire selection during an immune response. Immunity 10:485–492CrossRefPubMed

38.

Britten CM, Gouttefangeas C, Welters MJ et al (2008) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57:258–285

39.

Britten CM, Janetzki S, Ben-Porat L et al (2009) Harmonization guidelines for HLA-peptide multimer assays derived from results of a large-scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 58:1701–1713CrossRefPubMed

40.

Sun MY, Bowness P (2001) MHC class I multimers. Arthritis Res 3:265–269CrossRefPubMed

41.

Yao J, Bechter C, Wiesneth M et al (2008) Multimer staining of CMVpp65-specific T cells for diagnosis and therapeutic purpose—a comparative study. Clin Infect Dis 46:96–105CrossRef

42.

Casares S, Hurtado A, McEvoy RC et al (2002) Down-regulation of diabetogenic CD4⁺ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 3:383–391CrossRefPubMed

43.

Reijonen H, Novak EJ, Kochik S et al (2002) Detection of GAD65-specific T cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 51:1375–1382CrossRefPubMed

44.

Cobbold M, Khan N, Pourgheysari B et al (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202:379–386CrossRefPubMed

45.

Marmont AM, Horowitz MM, Gale RP et al (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120–2130PubMed

46.

Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112:4371–4383CrossRefPubMed

47.

Kolb HJ, Schattenberg A, Goldman JM et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041–2050PubMed

48.

Viola A, Lanzavecchia A (1996) T-cell activation determined by T-cell receptor number and tunable thresholds. Science 273:104–106CrossRefPubMed

49.

Sykulev Y, Joo M, Vturina I et al (1996) Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T-cell response. Immunity 4:565–571CrossRefPubMed

50.

Roback JD (2006) Vaccine-enhanced donor lymphocyte infusion. Hematology 486–491

51.

Boeckh M, Nichols WG, Papanicolaou G et al (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9:543–558CrossRefPubMed

52.

Langston AA, Redei I, Caliendo AM et al (2002) Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 99:1085–1088CrossRefPubMed

53.

Levy RB, Jones M, Cray C (1990) HSV-1 enhances GvHR-associated parent anti-F1 alloreactivity in vivo and in vitro. Cell Immunol 129:1–12CrossRefPubMed

54.

Boeckh M, Leisenring W, Riddell SR et al (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407–414CrossRefPubMed

55.

Kolb HJ, Schmid A, Barret AJ, Schendel DJ (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103:767–776CrossRefPubMed

56.

Riddell SR, Watanabe KS, Goodrich JM et al (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 257:238–241CrossRefPubMed

57.

Tiberghien P, Ferrand C, Lioure B et al (2001) Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97:63–72CrossRefPubMed

58.

Einsele H, Roosnek E, Rufer N et al (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916–3922CrossRefPubMed

59.

Walter EA, Greenberg PD, Gilbert MJ et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044CrossRefPubMed

60.

Mandigers CMPW, Verdonck LF, Meijerink JPP et al (2003) Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapse after allogeneic stem cell transplantation. Bone Marrow Transplant 32:1159–1163CrossRefPubMed

61.

Mackinnon S, Papadopoulos EB, Carabasi MH et al (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261–1268PubMed

62.

Bonini C, Ferrari G, Verzelletti S et al (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science 276:1719–1724CrossRefPubMed

63.

Thomis DC, Marktel S, Bonini C et al (2001) A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97:1249–1257CrossRefPubMed

64.

Molldrem JJ, Lee PP, Wang C et al (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018–1023CrossRefPubMed

65.

Wang X, Schmitt A, Germeroth L et al (2009) Generation of leukemia antigen-specific donor lymphocyte infusions powered by streptamer-based selection. Bone Marrow Transplant 43:S73

66.

Schmitt A, Tonn T, Busch DH et al (2009) Adoptive transfer and consequential selective reconstitution of streptamers-selected cytomegalovirus-specific CD8⁺ T cells leads to enduring virus clearance in patients after allogeneic stem cell transplantation. Bone Marrow Transplant 43:S246

Titel: Multimer technologies for detection and adoptive transfer of antigen-specific T cells
verfasst von: Rosaely Casalegno-Garduño
Anita Schmitt
Junxia Yao
Xinchao Wang
Xun Xu
Mathias Freund
Michael Schmitt
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2010
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0778-4

Springer Medizin

Multimer technologies for detection and adoptive transfer of antigen-specific T cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer

Tumors induce the formation of suppressor endothelial cells in vivo

Systemic dysregulation of CEACAM1 in melanoma patients

Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)

Assessment of the pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein FP3 with ELISA and BIACORE

Loci controlling lymphocyte production of interferon γ after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie